Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Stiefel, a GSK Company
With
GlaxoSmithKline
Topical corticosteroids have anti-inflammatory, immunosuppressive and antiproliferative properties. Clobetasol propionate foam 0.05% (Olux-E), a Class 1 corticosteroid, is formulated in an ethanol free petrolatum base that provides the benefits of a super-potent corticosteroid combined with moisturizing ingredients in the treatment of corticosteroid responsive dermatoses. The current study is designed to show efficacy and safety in the treatment of moderate to severe chronic hand dermatitis.
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Capable of understanding and willing to provide signed informed consent
Male or female at least 12 years of age at time of consent and at time of first dose.
Able to complete the study and to comply with study instructions.
Moderate to severe hand dermatitis.
Chronic hand dermatitis diagnosis must be at least 6 months
You may not be if
Female who is pregnant, trying to become pregnant, or breast feeding.
Currently diagnosed with allergic contact dermatitis.
Participated in a previous study of the same study product.
Had any major illness within 30 days before the screening/baseline visit.
Considered immunocompromised.
Has a clinically relevant history of or current evidence of abuse of alcohol or other drugs.
Considered unable or unlikely to attend the necessary visits.